The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

Christopher A. Eide, Lauren T. Adrian, Jeffrey W. Tyner, Mary Mac Partlin, David J. Anderson, Scott C. Wise, Bryan D. Smith, Peter A. Petillo, Daniel L. Flynn, Michael W.N. Deininger, Thomas O'Hare, Brian J. Druker

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Fingerprint

Dive into the research topics of 'The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL<sup>T315I</sup> and exhibits a narrow resistance profile'. Together they form a unique fingerprint.

Medicine & Life Sciences